摘要
目的探讨不同剂量聚乙二醇化重组人粒细胞刺激因子(pegylated recombinant human granulocyte-colony stimulating factor,PEG-rhG-CSF)的临床疗效、安全性与经济性,为临床用药提供参考。方法收集2017年1月―2018年12月在中国科学技术大学附属第一医院(安徽省立医院)化疗后发生IV度骨髓抑制的恶性肿瘤患者106例。按给药剂量不同分为两组,A组(PEG-rhG-CSF 3 mg)64例,B组(PEG-rhG-CSF 6 mg)42例,比较用药前后的临床疗效、不良反应,计算治疗成本,对两组治疗方案进行药物经济学最小成本分析。结果A组(PEG-rhG-CSF 3 mg)和B组(PEG-rhG-CSF 6 mg)的临床疗效和不良反应比较,差异无统计学意义(均有P>0.05)。A组和B组治疗方案的成本分别为1705元和3410元,A组(PEG-rhG-CSF 3 mg)治疗方案更经济。结论考虑到药物的有效性和经济学,A组(PEG-rhG-CSF 3 mg)治疗方案是治疗IV度骨髓抑制的最佳治疗方案。
Objective To evaluate the efficacy,safety and economics of myelosuppression treated by different doses of pegylated recombinant human granulocyte-colony stimulating factor(PEG-rhG-CSF),so as to provide reference for clinical use.Methods 106 patients with grade IV myelosuppression after chemotherapy from January 2017 to December 2018 were collected.According to different doses,patients were divided into two groups:64 cases in group A(PEG-rhG-CSF 3 mg)and 42 cases in group B(PEG-rhG-CSF 6 mg).Clinical efficacy and adverse reactions were compared,and treatment cost was calculated so that cost-minimization analysis in pharmacoeconomic was compared between the two groups.Results There was no significant difference in clinical efficacy and adverse reactions between group A and group B(all P>0.05).The cost of these two regimens was RMB 1705 for group A and RMB 3410 for group B.The regimen in group A was more economical.Conclusions The regimen in group A(PEG-rhG-CSF 3 mg)is the proper option for grade IV myelosuppression in China,considering the efficacy,safety,and cost-minimization analysis of the drug.
作者
傅昌芳
韩兴华
李岩
沈爱宗
FU Chang-fang;HAN Xing-hua;LI Yan;SHEN Ai-zong(Department of Pharmacy,the First Affiliated Hospital of USTC,Hefei 230001,China;Department of Oncology,the First Affiliated Hospital of USTC,Hefei 230001,China)
出处
《中华疾病控制杂志》
CAS
CSCD
北大核心
2020年第8期956-960,共5页
Chinese Journal of Disease Control & Prevention
基金
CSCO-齐鲁肿瘤研究基金(Y-Q2017-077)。